Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 196 participants.

Also called NCT02506868

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 196 participants (enrolled count) (from the registry)
Sponsor
  • Biocad Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02506868
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02506868. Randomized; quadruple masking; primary purpose treatment. Start 2015-08-08 (actual); primary completion 2017-01-08 (actual). Results posted on 2019-05-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients
Condition
End Stage Renal Failure on Dialysis
Condition
Anemia
Intervention (Drug)
Darbepoetin alfa
Lead sponsor
Biocad (class: industry)

Record details

Record id
cardio:ct-nct02506868
Content hash
bf155d0f7a4590209f537e79de8aa2f9800f5b1d3adb9c0d031349a7f1449837